Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 Positive Malignant Carcinoma of Breast”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02488564
What this trial is testing

Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer

Who this might be right for
HER-2 Positive Breast Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 49
Testing effectiveness (Phase 2)Active Not RecruitingNCT04225117
What this trial is testing

Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Who this might be right for
Locally Advanced or Metastatic Malignant Solid Tumors
Astellas Pharma Global Development, Inc. 329
Large-scale testing (Phase 3)Ended earlyNCT03199885
What this trial is testing

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast AdenocarcinomaMetastatic HER2-Positive Breast CarcinomaRecurrent Breast Adenocarcinoma+5 more
National Cancer Institute (NCI) 190
Large-scale testing (Phase 3)Looking for participantsNCT07043725
What this trial is testing

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. 544
Testing effectiveness (Phase 2)Ended earlyNCT02379585
What this trial is testing

Fasting on Newly Diagnosed Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Western Regional Medical Center 8
Testing effectiveness (Phase 2)UnknownNCT05154396
What this trial is testing

Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Chinese Academy of Medical Sciences 60
Testing effectiveness (Phase 2)Study completedNCT00436566
What this trial is testing

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Who this might be right for
Breast CancerCardiac Toxicity
Mayo Clinic 122
Very early researchStudy completedNCT01875666
What this trial is testing

Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

Who this might be right for
Breast Neoplasms
UNC Lineberger Comprehensive Cancer Center 26
Testing effectiveness (Phase 2)Looking for participantsNCT05306041
What this trial is testing

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
GBG Forschungs GmbH 170
Not applicableUnknownNCT06135194
What this trial is testing

Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior Pyrotinib

Who this might be right for
Breast Cancer
Beijing 302 Hospital 30
Not applicableUnknownNCT05656079
What this trial is testing

To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study

Who this might be right for
Breast Cancer
Shanghai Pudong Hospital 204
Large-scale testing (Phase 3)Active Not RecruitingNCT04873362
What this trial is testing

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 1,188
Testing effectiveness (Phase 2)Ended earlyNCT00817362
What this trial is testing

Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer

Who this might be right for
Breast CancerHER2 Positive Breast CancerMetastatic Breast Cancer+1 more
Infinity Pharmaceuticals, Inc. 29
Early research (Phase 1)Study completedNCT01471847
What this trial is testing

A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab

Who this might be right for
Locally Advance Breast Cancer (LABC)Metastatic Breast Cancer (MBC)
Novartis Pharmaceuticals 5
Testing effectiveness (Phase 2)Study completedNCT00331552
What this trial is testing

Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+1 more
University of Washington 30
Not applicableEnded earlyNCT04106167
What this trial is testing

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Who this might be right for
Advanced Solid TumorLymphomaGastric Cancer+15 more
Fate Therapeutics 20
Testing effectiveness (Phase 2)Study completedNCT01855828
What this trial is testing

Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer

Who this might be right for
Her2-Positive Breast Cancer
Yale University 50
Testing effectiveness (Phase 2)Ended earlyNCT04278144
What this trial is testing

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Who this might be right for
HER2-positive Solid TumorsHER2-positive Breast CancerHER2-positive Colorectal Cancer+2 more
Bolt Biotherapeutics, Inc. 175
Not applicableLooking for participantsNCT05314114
What this trial is testing

Selective Omission of Axillary Surgery in Triple-negative and HER2-positive Breast Cancer After NACT

Who this might be right for
Breast Cancer Female
Peking University 136
Testing effectiveness (Phase 2)Looking for participantsNCT06927180
What this trial is testing

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Henan Cancer Hospital 180
Next Page